Accelerator Nordic AB

PledPharma AB has started a clinical phase II study

Pressmeddelande   •   Dec 14, 2009 11:22 CET

PledPharma AB has started a clinical phase II study

The first patient included in a clinical study in patients with acute myocardial infarction

Earlier this autumn, PledPharma AB received approval from the Swedish Medical Products Agency (MPA; Läkemedelsverket) and the local Ethical Committee to start a clinical phase II trial in patients with Acute Myocardial Infarction (AMI). The first patient has now been included in the trial.

The trial is run at the County Hospital Ryhov in Jönköping, Sweden, and Dr Jan-Erik Karlsson at the Department of Internal Medicine, serves as the principal investigator in the trial.

Active reopening of occluded coronary arteries by primary percutaneous coronary intervention (PCI) has led to reduction in infarct size, but there is still a need for improvement.

The aim of the present study is to test whether PP-099, a LowMEM (Low Molecular weight

Enzyme Mimetic), further reduces myocardial infarct size in patients undergoing primary PCI. Preclinical studies indicate that PP-099 may reduce myocardial infarct size by more than 50%.

“The study may lead to a more effective reduction in infarct size during treatment with PCI, and thereby decrease the incidence and severity of secondary heart failure after AMI”, says Professor Per Jynge, Medical Director in PledPharma AB

Over the last 30 years mortality in AMI has been reduced from 25% to less than 10%, but due to remaining myocardial injury the number of surviving patients that develop chronic heart failure is rising. It is hence an unmet medical need to find treatments that can further reduce the myocardial injury.

For further information, please contact:

Per Jynge, Medical Director, PledPharma AB, +47 735 115 55

Jan Olof G. Karlsson, Chief Scientific Officer, PledPharma AB, +46 733 304 624

PledPharma AB develops new medicines based on Low Molecular weight Enzyme Mimetics

(LowMEM) with an initial candidate PP-095 for oncology. PP-095 protects against dose-limiting side effects during cancer therapy with cytostatic drugs, without diminishing the anticancer effect. PP-095 entered clinical phase II trials in cancer patients in 2008. In addition to cancer treatment, LowMEMs have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases. For more information see www.pledpharma.se